The possible role of burden of therapy on the risk of myeloma extramedullary spread

S. Mangiacavalli, A. Pompa, V. Ferretti, C. Klersy, F. Cocito, M. Varettoni, C. S. Cartia, M. Cazzola, A. Corso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (>/=6 vs 2 vs
Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalAnnals of Hematology
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Recurrence
Therapeutics
Multiple Myeloma
Cohort Studies
Multivariate Analysis
History
Bone and Bones
Survival
Neoplasms

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Bortezomib/administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma/diagnosis/drug therapy/mortality
  • Neoplasm Recurrence, Local/diagnosis/drug therapy/mortality
  • Retrospective Studies
  • Risk Factors
  • Sarcoma, Myeloid/diagnosis/drug therapy/mortality
  • Survival Rate/trends
  • Thalidomide/administration & dosage/analogs & derivatives
  • Extramedullary
  • Myeloma
  • Novel agents
  • Relapse

Cite this

The possible role of burden of therapy on the risk of myeloma extramedullary spread. / Mangiacavalli, S.; Pompa, A.; Ferretti, V.; Klersy, C.; Cocito, F.; Varettoni, M.; Cartia, C. S.; Cazzola, M.; Corso, A.

In: Annals of Hematology, Vol. 96, No. 1, 01.01.2017, p. 73-80.

Research output: Contribution to journalArticle

@article{abfbb098520a44da982509929543b498,
title = "The possible role of burden of therapy on the risk of myeloma extramedullary spread",
abstract = "Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 {\%} with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (>/=6 vs 2 vs",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Bortezomib/administration & dosage, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma/diagnosis/drug therapy/mortality, Neoplasm Recurrence, Local/diagnosis/drug therapy/mortality, Retrospective Studies, Risk Factors, Sarcoma, Myeloid/diagnosis/drug therapy/mortality, Survival Rate/trends, Thalidomide/administration & dosage/analogs & derivatives, Extramedullary, Myeloma, Novel agents, Relapse",
author = "S. Mangiacavalli and A. Pompa and V. Ferretti and C. Klersy and F. Cocito and M. Varettoni and Cartia, {C. S.} and M. Cazzola and A. Corso",
note = "LR: 20170201; JID: 9107334; 4Z8R6ORS6L (Thalidomide); 69G8BD63PP (Bortezomib); F0P408N6V4 (lenalidomide); OTO: NOTNLM; 2015/12/30 00:00 [received]; 2016/10/02 00:00 [accepted]; 2016/10/22 06:00 [pubmed]; 2017/02/02 06:00 [medline]; 2016/10/22 06:00 [entrez]; ppublish",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00277-016-2847-z [doi]",
language = "English",
volume = "96",
pages = "73--80",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The possible role of burden of therapy on the risk of myeloma extramedullary spread

AU - Mangiacavalli, S.

AU - Pompa, A.

AU - Ferretti, V.

AU - Klersy, C.

AU - Cocito, F.

AU - Varettoni, M.

AU - Cartia, C. S.

AU - Cazzola, M.

AU - Corso, A.

N1 - LR: 20170201; JID: 9107334; 4Z8R6ORS6L (Thalidomide); 69G8BD63PP (Bortezomib); F0P408N6V4 (lenalidomide); OTO: NOTNLM; 2015/12/30 00:00 [received]; 2016/10/02 00:00 [accepted]; 2016/10/22 06:00 [pubmed]; 2017/02/02 06:00 [medline]; 2016/10/22 06:00 [entrez]; ppublish

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (>/=6 vs 2 vs

AB - Extramedullary relapse (EMR) represents a poor prognostic marker in the course of multiple myeloma (MM). We reviewed data from 329 patients, diagnosed between 2000 and 2010, without extramedullary disease at onset to explore possible risk factors for EMR. The median overall survival of our study cohort was 6.4 years. The risk of EMR was 28 % with a median time from diagnosis to first EMR of 2.2 years (0.2-9.1 years). Patients with soft tissue masses located in extra-osseous organs (EMR-S) showed the worst outcome, compared to those with tumor masses arising from adjacent bone (EMR-B) (median OS 1.6 vs 2.4 years, p = 0.006). In addition, patients with EMR-S showed a significant trend for further development of extramedullary masses in a very short time (3.7 vs 5.7 months for EMR-B, p = 0.043). Multivariate analysis failed to identify any clinically presenting features predictive for EMR. The occurrence of EMR was higher in patients with more complex treatment history, defined on the basis of longer treatment duration (>/=6 vs 2 vs

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Bortezomib/administration & dosage

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma/diagnosis/drug therapy/mortality

KW - Neoplasm Recurrence, Local/diagnosis/drug therapy/mortality

KW - Retrospective Studies

KW - Risk Factors

KW - Sarcoma, Myeloid/diagnosis/drug therapy/mortality

KW - Survival Rate/trends

KW - Thalidomide/administration & dosage/analogs & derivatives

KW - Extramedullary

KW - Myeloma

KW - Novel agents

KW - Relapse

U2 - 10.1007/s00277-016-2847-z [doi]

DO - 10.1007/s00277-016-2847-z [doi]

M3 - Article

VL - 96

SP - 73

EP - 80

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -